Triumeq Dosage

Screening for HLA-B*5701 Allele prior to Starting TRIUMEQ

Screen for the HLA‑B*5701 allele prior to initiating therapy with TRIUMEQ [see Boxed Warning, Warnings and Precautions (5.1)].

Pregnancy Testing before Initiation of TRIUMEQ

​Perform pregnancy testing before initiation of TRIUMEQ in adolescents and adults of childbearing potential [see Warnings and Precautions (5.6), Use in Specific Populations (8.1, 8.3)].

Recommended Dosage

​TRIUMEQ is a fixed-dose combination product containing 600 mg of abacavir, 50 mg of dolutegravir, and 300 mg of lamivudine. The recommended dosage regimen of TRIUMEQ in adults and in pediatric patients weighing at least 40 kg is one tablet once daily orally with or without food.

Dosage Recommendation with Certain Concomitant Medications

The dolutegravir dose (50 mg) in TRIUMEQ is insufficient when coadministered with medications listed in Table 1 that may decrease dolutegravir concentrations; the following dolutegravir dosage regimen is recommended.

Not Recommended Due to Lack of Dosage Adjustment

Because TRIUMEQ is a fixed-dose tablet and cannot be dose adjusted, TRIUMEQ is not recommended in:

•

patients with creatinine clearance less than 50 mL per minute [see Use in Specific Populations (8.6)].

•

patients with mild hepatic impairment. TRIUMEQ is contraindicated in patients with moderate or severe hepatic impairment [see Contraindications (4), Use in Specific Populations (8.7)].